Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2016-04-22FDA Approved: POMALYST — Supplemental Application (Celgene Corporation)
The FDA approved a supplemental application for POMALYST (pomalidomide) submitted by Celgene Corporation. This action updates the drug's ind…
-
EMA approval · 2016-04-01New treatment for patients with multiple myeloma
EMA announces a new treatment option for patients with multiple myeloma, indicating a new drug has been authorized or recommended for use in…
-
FDA approval · 2016-03-25FDA Approved: ZOLEDRONIC ACID — Supplemental Application (Sagent Pharmaceuticals)
FDA approved a supplemental application for zoledronic acid filed by Sagent Pharmaceuticals.
-
FDA approval · 2016-03-10FDA Approved: EVOMELA — Original Application (Acrotech Biopharma Inc)
FDA approved EVOMELA (melphalan liposome injection) from Acrotech Biopharma as the original application, providing the first approval of thi…
-
EMA approval · 2016-01-29EMA fast-tracks treatment of multiple myeloma for approval in EU
EMA expedites evaluation of a multiple myeloma treatment for potential approval in the European Union.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2016-01-21FDA Approved: KYPROLIS — Supplemental Application (Onyx Pharmaceuticals, Inc.)
The FDA approved a Supplemental Application for KYPROLIS (carfilzomib) submitted by Onyx Pharmaceuticals, Inc.
-
FDA approval · 2015-12-01FDA Approved: POMALYST — Supplemental Application (Celgene Corporation)
FDA approved a supplemental application for POMALYST (pomalidomide) from Celgene Corporation, resulting in updated labeling for the product.
-
FDA approval · 2015-11-30FDA Approved: EMPLICITI — Original Application (E.R. Squibb & Sons, L.L.C.)
The FDA approved Empliciti (elotuzumab) under original BLA 761035 for the treatment of multiple myeloma in adults, in combination with lenal…
-
FDA approval · 2015-11-20FDA Approved: NINLARO — Original Application (Takeda Pharmaceuticals America, Inc.)
The FDA approved NINLARO (ixazomib) in its original application from Takeda Pharmaceuticals America, Inc. for the treatment of multiple myel…
-
FDA approval · 2015-11-16FDA Approved: DARZALEX — Original Application (Janssen Biotech, Inc.)
FDA approved the original application for DARZALEX (daratumumab) from Janssen Biotech, Inc., establishing its use for treating multiple myel…
-
FDA approval · 2015-10-19FDA Approved: ZOLEDRONIC ACID — Supplemental Application (BPI Labs LLC)
FDA approves a supplemental application for zoledronic acid from BPI Labs LLC under ANDA 202930. This action supports continued availability…
-
FDA approval · 2015-10-09FDA Approved: DOXORUBICIN HYDROCHLORIDE LIPOSOME — Supplemental Application (Baxter Healthcare Company)
FDA approved Baxter's supplemental NDA for doxorubicin hydrochloride liposome.
-
FDA approval · 2015-09-21FDA Approved: ZOLEDRONIC ACID — Supplemental Application (Dr. Reddy's Laboratories Limited)
The FDA approved a supplemental application for zoledronic acid from Dr. Reddy's Laboratories Limited.
-
FDA approval · 2015-08-04FDA Approved: MOZOBIL — Supplemental Application (Sanofi-Aventis U.S. LLC)
FDA approves a supplemental application for MOZOBIL (plerixafor) from Sanofi-Aventis U.S. LLC. The action updates the product's labeling and…
-
FDA approval · 2015-07-24FDA Approved: KYPROLIS — Supplemental Application (Onyx Pharmaceuticals, Inc.)
FDA approved a supplemental application for KYPROLIS (carfilzomib) filed by Onyx Pharmaceuticals, expanding its approved label.
-
EMA approval · 2015-06-26First HDAC inhibitor for treatment of multiple myeloma recommended for approval in EU
The EMA recommends approval of the first histone deacetylase (HDAC) inhibitor for the treatment of multiple myeloma in the European Union.
-
FDA approval · 2015-04-24FDA Approved: KYPROLIS — Supplemental Application (Onyx Pharmaceuticals, Inc.)
FDA approved a supplemental application for KYPROLIS (carfilzomib) submitted by Onyx Pharmaceuticals, Inc.
-
FDA approval · 2015-04-23FDA Approved: POMALYST — Supplemental Application (Celgene Corporation)
The FDA approved a supplemental application for POMALYST (pomalidomide) by Celgene Corporation, resulting in changes to the drug's labeling.
-
FDA approval · 2015-04-09FDA Approved: ZOLEDRONIC ACID — Supplemental Application (Dr.Reddy's Laboratories Ltd)
FDA approved a supplemental application for zoledronic acid from Dr. Reddy's Laboratories Ltd (ANDA 091363), granting regulatory approval of…
-
FDA approval · 2015-03-27FDA Approved: KYPROLIS — Supplemental Application (Onyx Pharmaceuticals, Inc.)
FDA approved a supplemental application for KYPROLIS (carfilzomib) filed by Onyx Pharmaceuticals, Inc., updating the drug’s labeling. The ac…
-
FDA approval · 2014-10-25FDA Approved: CYCLOPHOSPHAMIDE — Supplemental Application (Civica, Inc.)
FDA approved a supplemental application for Civica, Inc. to market a generic cyclophosphamide product.
-
FDA approval · 2014-09-12FDA Approved: THALOMID — Supplemental Application (Celgene Corporation)
FDA approved a supplemental application for THALOMID (thalidomide) submitted by Celgene Corporation, resulting in an expanded indication.
-
FDA approval · 2014-09-12FDA Approved: POMALYST — Supplemental Application (Celgene Corporation)
FDA approved a supplemental application for POMALYST (pomalidomide) filed by Celgene Corporation. The action updates the drug’s labeling to …
-
FDA approval · 2014-06-02FDA Approved: KYPROLIS — Supplemental Application (Onyx Pharmaceuticals, Inc.)
FDA approves a supplemental application for KYPROLIS (carfilzomib) from Onyx Pharmaceuticals. This action finalizes an update to KYPROLIS's …
-
FDA approval · 2014-03-13FDA Approved: POMALYST — Supplemental Application (Celgene Corporation)
The FDA approved a supplemental application for POMALYST (pomalidomide) submitted by Celgene Corporation. This represents an update to the p…